Zura Bio Ltd ZURA

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) Nasdaq

We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies.

Our strategy is to identify immune-mediated diseases in which translational and clinical evidence supports the role of specific biological pathways in disease pathogenesis. We focus on targets for which human data, including biomarker findings, genetic associations and prior clinical studies, inform therapeutic rationale and development decisions. We seek to advance product candidates in therapeutic areas where there remains meaningful unmet medical need and where, if clinical benefit is demonstrated, there may be potential for commercial relevance.

Last close 6.23 2026-09-04
Market cap $597.0M 2026-06-30 share count
52-week range 1.88 - 7.44

Valuation FY2025 figures against the last close

P/S
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS-1.06

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
R&D $42.1M$24.4M$44.0M$23.7M
SG&A $33.2M$30.8M$18.6M$3.5M
Total operating expenses $75.2M$55.2M$62.6M$27.2M
Operating income -$75.2M-$55.2M-$62.6M-$27.2M
Pre-tax income -$68.7M-$52.4M-$60.6M-$27.3M
Income tax $0$0
Net income -$68.7M-$52.4M-$60.4M-$25.7M
EPS, basic -1.06-0.60-2.09-141.97
EPS, diluted -1.06-0.60-2.09-141.97
Shares, diluted (wtd. avg.) $94.2M$75.1M$33.1M$228.1K

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents $109.4M$176.5M$99.8M$1.6M$729.2K$0
Total current assets $112.3M$178.7M$100.8M$1.8M$1.2M
Property, plant and equipment $126.0K$91.0K
Total assets $113.9M$179.5M$100.8M$5.3M$140.6M
Accounts payable $1.3M$733.0K$2.7M$2.0M$69.9K
Total current liabilities $12.4M$19.5M$20.3M$14.8M$272.3K
Total liabilities $12.4M$19.5M$21.3M$14.8M$10.4M
Retained earnings -$224.5M-$155.9M-$103.5M-$32.1M-$9.2M
Total equity $101.5M$146.8M$60.9M-$32.1M-$9.2M$0

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Operating cash flow -$64.8M-$28.1M-$15.1M-$1.2M
Depreciation and amortisation $49.0K$9.0K
Stock-based compensation $12.3M$16.8M$7.5M$334.0K
Capital expenditure $113.0K$75.0K
Investing cash flow -$113.0K-$5.1M-$8.0M-$12.0M
Financing cash flow -$2.2M$109.8M$121.3M$14.8M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-032080.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $236.38B 30.7x 10.0%
GILD GILEAD SCIENCES, INC. $187.23B 22.3x 2.4%
MRNA Moderna, Inc. $58.11B -39.9%
RVMD Revolution Medicines, Inc. $45.01B
BIIB BIOGEN INC. $32.60B 25.1x 2.2%
SCNI Scinai Immunotherapeutics Ltd. $25.80B 99.2%
NBIX NEUROCRINE BIOSCIENCES INC $15.82B 33.3x 21.4%
EXEL EXELIXIS, INC. $14.62B 21.2x 7.0%